17,261 trials
Multiple Sclerosis, Chronic Progressive
Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants
Anesthesia, General · Neuromuscular Blockade
Primary: Neuromuscular Recovery — 5.7; 3.1; 1.1; 43.7 Minutes
Urinary Tract Infections · Urinary Retention Postoperative · Pelvic Organ Prolapse
Primary: Incidence of Urinary Track Infection (UTI) — 62; 71 Participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 40.2 Percentage of Participants
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Stage III Cutaneous Melanoma AJCC v7 · Stage IIIA Cutaneous Melanoma AJCC v7 · Stage IIIB Cutaneous Melanoma AJCC v7
Primary: Number of Participants in Each Clinical Response Category — 2; 2; 2; 4 Participants
Chronic Pain · Alcohol Use, Unspecified · HIV Infections
Primary: Change in Past Week Pain Severity — -0.97; -2.12; -1.85 units on a scale
Covid19
Primary: Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29 — 0; 3; 0; 0 Participants
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
Carcinoid Tumor
Primary: Progression Free Survival — 11.8 months
Proteinuria
Primary: Change in Proteinuria by 25% — 8 Participants
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
T2DM (Type 2 Diabetes Mellitus)
Primary: Change From Baseline of HbA1C (Glycated Hemoglobin) — -0.13; -0.60; -0.59; -0.51 percent HbA1C
Castration-resistant Prostate Cancer
Primary: Number of Participants With Toxicities That Required the Addition of Prednisone to Manage Symptoms of Persistent or Severe Mineralocorticoid Excess — 38; 28; 15; 11…
Hereditary Angioedema
Primary: The Mean Time Normalized Number of HAE Attacks Per Month in Subjects With C1-INH HAE During Treatment Period 1 — 4.24; 0.48; 0.05; 0.35 Number of HAE attacks per month